Drug localisation is still one of the main challenges in treating pathologies affecting
cartilage; poly-beta-amino-esters (PBAEs) drug conjugates are a possible solution; …

Osteoarthritis (OA) is a synovial inflammatory condition characterized by cartilage
destruction and osteophyte formation. Macrophages play a central role in OA pathogenesis …

Piroxicam (PX), a main member of non-steroidal anti-inflammatory drugs (NSAIDs), is mainly
used orally, which causes side effects of the gastrointestinal tract. It also has systemic effects …

Cartilage repair strategies are evolving at a fast pace with technology development. Matrices
that offer multifaceted functions and a full adaption to the cartilage defect are of pivotal …

Osteoarthritis (OA) is a leading cause of disability in elderly individuals. As a common
chronic degenerative joint disease, OA is typically characterized by articular cartilage …

In patients with mild osteoarthritis (OA), two to four monthly injections are required for 6
months due to the degradation of hyaluronic acid (HA) by peroxidative cleavage and …

Abstract Receptor-interacting protein 2 (RIP2) is a key mediator implicated in multiple
cellular processes, and its dysregulation has been recently reported in colitis, asthma and …

Nanoparticles are a promising approach for improving intra-articular drug delivery and
tissue targeting. However, techniques to non-invasively track and quantify their …

A major reason that hinders the clinical application of disease-modifying osteoarthritis drugs
(DMOADs) is the unmet challenges in their effective delivery to cartilage. Cationic …

Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disorder with synovitis and
articular pathology as its primary expositions. Leflunomide (Lfd) is an anti-rheumatic drug …